SCHEMBL28041713

SCHEMBL28041713

CC(C)n1cc(C(=O)O)nc1Br

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.41
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
HCAR3 P49019 2/20 0.34
KDM4E B2RXH2 4/20 0.33
ALOX15 P16050 2/20 0.33
TSHR P16473 2/20 0.33
ACMSD Q8TDX5 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HIF1A Q16665 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
MCL1 Q07820 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18040232 0.83 RXFP1 (0.38) RXFP1PTGS1PTGS2HCAR3HCAR2
SCHEMBL15903442 0.81 GAA (0.37) KDM4EALDH1A1CA12CA1CA2
SCHEMBL13733079 0.79 RXFP1 (0.39) RXFP1PTGS1PTGS2HCAR3KDM4E
SCHEMBL15142107 0.77 CYP1A2 (0.46) RXFP1KDM4EALDH1A1SMN1; SMN2
SCHEMBL14477886 0.75 ALDH1A1 (0.33) RXFP1PTGS1PTGS2HCAR3KDM4E
SCHEMBL15903278 0.75 HCAR2 (0.35) RXFP1PTGS1PTGS2HCAR3KDM4E
SCHEMBL375420 0.75 RXFP1 (0.45) RXFP1PTGS1PTGS2KDM4EALOX15
SCHEMBL25274273 0.72 RXFP1 (0.42) RXFP1PTGS1PTGS2KDM4EALOX15
SCHEMBL28041712 0.70 RXFP1 (0.41) RXFP1PTGS1PTGS2KDM4EALOX15
SCHEMBL18865608 0.70 ADORA3 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105209467-B Imidazopyrrolidinone derivatives and their use in the treatment of disease 诺华股份有限公司 2018-06-08 CN disclosed
CN-105209467-A Imidazopyrrolidinone derivatives and their use in the treatment of disease NOVARTIS AG 2015-12-30 CN disclosed